Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRL-305 in r/r multiple myeloma
NCT07248176Phase 1Recruiting
- Sponsor
- BRL Medicine Inc.
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA-UCART in multiple myeloma (MM), sponsored by BRL Medicine Inc. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 24 months. Started Apr 2025; status: recruiting.
02
Drugs
BCMA-UCART
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07248176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07248176.